DDrare: Database of Drug Development for Rare Diseases

Searched query = "Retinitis pigmentosa", "Rod dystrophy", "Rod-Cone Dystrophy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 100 µg Brimonidine Tartrate Implant; 200 µg Brimonidine Tartrate Implant; 400 µg Brimonidine Tartrate Implant; 4D-125 IVT Injection; 9715X; 9741X; 9742X; AAV-RPGR; AAV2-REP1; AAV2/5-hPDE6B; AAV2/5-hRKp.RPGR; AAV8-RPGR; ALLOGENEIC NEURAL RETINA-DERIVED HUMAN NEURAL RETINAL PROGENITOR CELLS EX VIVO EXPANDED; Acetate; Acetazolamide; Aflibercept; Alga Dunaliella Bardawil; Alga Dunaliella Bardawil powder; Alga Dunaliella Bardawill; Antioxidants; BMMNCs; BS01; Betamethasone; Brimonidine; Brimonidine Tartrate; Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System; CD34+ bone marrow stem cells intravitreal; CIRCADIN 2 mg comprimidos de liberación prolongada; CNS10-NPC implantation; CNTO 2476; COQUN; CPK850; Cannabis; Carbidopa; Cholesterol; Ciliary Neurotrophic Factor Implant NT-501; Ciliary neurotrophic factor; Circadin; Circadin 2 mg; Combination Product: PRP combined Magnovision; Compound thrombosis capsule sig: 1.5g/tid; Conditioned Medium (CM); Continuous oxygen; Cornstarch; Cornstarch control; Cyclosporine; Cysteine; DAC; DDS; Device: Medmont Darl Adapted Chromatic (DAC); Device: MonCvONE electrophysiology; Device: RetMap, RM Electrode; Device: blue light-absorbing sunglasses; Device: dexamethasone injection; Dexamethasone; Diagnostic Test: Ocular Coherence Tomography-Angiography (OCT-A); Docosahexaenoic acid; Dorzolamide; Eylea; Fluocinolone; Fluocinolone Acetonide; Fluocinolone acetonide; GS030-DP; Ginkgo; Ginkgo biloba; Ginkgo biloba pills sig: 300mg/tid; HORA-PDE6B (AAV2/5.hPDE6B); HRPC; HRPC DP; Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE); Human Retinal Progenitor Cells Drug Product; Human primary Retinal Pigment Epithelial (HuRPE) cells; Human retinal progenitor cells; Hydroxychloroquine; Hydroxychloroquine higher dose; Hydroxychloroquine lower dose; Iluvien; Intravitreal injection of Autologous bone marrow Stem Cell; Intravitreal injection of autologous bone marrow stem cells; Lentiviral vector containing MYO7A gene; Lentiviral vector containing the human MY07A gene; Levodopa; Levodopa-carbidopa; Lutein; Lutein (10 or 30 mg/day) capsules; Lycium Barbarum; MELATONIN; Melatonin; Minocycline; N-Acetyl Cysteine (NAC); NAC; NAC effervescent tablets; NPI-001; NT-501; Nerve Growt Factor - 2.5S; Nerve Growth Factor; Nilvadipine; Null; Nutritional Supplement; Other: Mock injection; Other: Observational; Other: Sham (no implant); Other: Sham procedure; Other: Sham-procedure (dose cohort 1&2 only); Other: Standard of Care Sildenafil; Other: Subconjunctival injection of saline; Other: Sugar pill; Other: Visual Acuity (VA); Oxygen; PRP; PS; Phosphate; Platelet rich plasma; Procedure: Sham; Procedure: hyperbaric oxygen therapy; QLT091001; QR-1123; QR-421a; RAAV.hPDE6A vector; RAAV2tYF-GRK1-RPGR; RECOMBINANT HUMAN NERVE GROWTH FACTOR (RHNGF); RST-001; Recombinant adeno-associated viral vector serotype 2.7m8 containing the ChrimsonR-tdTomato gene; Recombinant human Nerve Growth Factor (rhNGF); Retinal pigment epitheliums transplantation; RhNGF; RhNGF 180 µg/ml eye drops solution; RhNGF 60 µg/ml eye drops solution; SAR421869; Sildenafil; Sodium valproate; Stem Cell Transplantation; Stem/progenitor cells transplantation; Subretinal injection of rAAV.hPDE6A; Subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP); Timrepigene emparvovec; Tocoferol; Triamcinolone; Twice-daily dosage with 0.5% cyclosporine-A eyedrops; UF-021; UF-021 (isopropyl unoprostone); UF-021(isopropyl unoprostone); Umbilical Cord Mesenchymal Stem Cell (UC-MSC); Unoprostone; UshStat; UshStat (SAR421869); VA; Valproate; Valproic Acid; Valproic acid; Vehicle eye drops; Vitamin A; Vitamin AD sig: 1 tablet/tid; Vitamin B sig: 10mg/tid; Vitamin E; Wharton's jelly derived mesenchymal stem cell; Zuretinol Acetate; Zuretinol acetate

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2012-002574-31-FR (EUCTR)	25/10/2013	15/05/2014	Study of SAR421869 in Patients With Retinitis Pigmentosa associated with Usher Syndrome Type 1B	A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected SAR421869, Administered to Patients with Retinitis Pigmentosa Associated with Usher Syndrome Type 1B	Retinitis Pigmentosa, associated with Ushers Syndrome Type 1B. MedDRA version: 20.0;Level: PT;Classification code 10038914;Term: Retinitis pigmentosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0;Classification code 10063396;Term: Usher's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]		sanofi-aventis recherche & développement	NULL	Not Recruiting			Female: yes Male: yes	27	Phase 1;Phase 2	United States;France
2	NCT01505062 (ClinicalTrials.gov)	March 26, 2012	4/1/2012	Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B	A Phase I/IIA Dose Escalation Safety Study of Subretinally Injected SAR421869, Administered to Patients With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B	Usher Syndrome;Retinitis Pigmentosa	Drug: SAR421869	Sanofi	NULL	Terminated	6 Years	N/A	All	9	Phase 1;Phase 2	United States;France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2012-002574-31-FR
(EUCTR)

25/10/2013

15/05/2014

Study of SAR421869 in Patients With Retinitis Pigmentosa associated with Usher Syndrome Type 1B

A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected SAR421869, Administered to Patients with Retinitis Pigmentosa Associated with Usher Syndrome Type 1B

Retinitis Pigmentosa, associated with Ushers Syndrome Type 1B.
MedDRA version: 20.0;Level: PT;Classification code 10038914;Term: Retinitis pigmentosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 20.0;Classification code 10063396;Term: Usher's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]

sanofi-aventis recherche & développement

NULL

Not Recruiting

Female: yes
Male: yes

Phase 1;Phase 2

United States;France

NCT01505062
(ClinicalTrials.gov)

March 26, 2012

4/1/2012

Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B

A Phase I/IIA Dose Escalation Safety Study of Subretinally Injected SAR421869, Administered to Patients With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B

Usher Syndrome;Retinitis Pigmentosa

Drug: SAR421869

Sanofi

NULL

Terminated

6 Years

N/A

All

Phase 1;Phase 2

United States;France